Immunology Devices Panel meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA advisory panel meeting August 19 in Rockville, Maryland to discuss draft guidances on anti-nuclear antibodies, anti-thyroid antibodies, and alpha-fetaprotein for neural tube defects. The panel will also discuss points-to-consider documents on "immunohistochemical antibody products and tumor markers (carcinoembryonic antigen, alphafetaprotein, and prostate specific antigen) for monitoring." The panel's agenda also includes open and closed discussion on "pending or future device applications." For more information, contact Peter Maxim at 301/594-1293
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.